Compare Estee Lauder Companies Inc (EL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs GeneDx Holdings Corp — how do they compare? Estee Lauder Companies Inc trades at $98.23 (market cap $34.17B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Estee Lauder Companies Inc is far larger — about 16.9× GeneDx Holdings Corp's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and GeneDx Holdings Corp for 19 Days on average.
| EL | WGS | |
|---|---|---|
Market Cap | $34.17B | $2.02B |
Volume | 3,921,497 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $167.51 |
52-Week Low | $67.23 | $34.51 |
Typical Hold Time | 122 Days | 19 Days |
Enterprise Value | $39.92B | $2.05B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $97.81, up 3.56% with recent earnings beats but faces fundamental challenges including a net loss of $1.13B in 2025. The stock shows neutral technical signals with support at $90 and resistance at $98, while analyst consensus remains positive with a $103 price target. Recent developments include AI partnerships and leadership changes aimed at revitalizing the brand.
The outlook hinges on margin recovery and revenue stabilization, with 2026 projections showing a return to profitability. Key risks include competitive pressures and execution of turnaround strategy, but institutional sentiment remains cautiously optimistic given the company's strong brand portfolio and digital initiatives.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
